MALLADI LIMITED

What MALLADI LIMITED does

Malladi Drugs & Pharmaceuticals Limited is a privately held Indian pharmaceutical manufacturer founded in 1980, headquartered in Chennai, Tamil Nadu, and operating three manufacturing facilities in Ranipet, Tamil Nadu (M1 and M3) and Renigunta, Andhra Pradesh (M5). The company produces Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, chiral building blocks, and specialty chemicals — with global leadership positions in Phenylephrine and Pseudoephedrine verified by the United States Pharmacopeia. Manufacturing is anchored in proprietary capabilities spanning fermentation technology, chiral chemistry, bio-transformation, flow chemistry, and advanced analytical instrumentation (NMR, LC-MS/MS, GC-MS, FTIR).

Malladi serves pharmaceutical companies across 60+ countries with 85% of revenue derived from exports. Its regulatory footprint — 22 Drug Master Files filed with the US FDA and other agencies (EDQM, ANSM, KFDA, TGA) and 6 CEP certifications — supports sales into highly regulated markets. Beyond merchant API supply, Malladi offers contract manufacturing, custom synthesis, and analytical chemistry services including characterization & impurity profiling, method development & validation, and quality assurance, supported by an R&D center near Chennai.

The business model is B2B enterprise sales of APIs and intermediates under quote-based pricing, with custom synthesis and CMC dossier preparation offered as project-based services. Distribution is direct to pharmaceutical manufacturers globally, with no public pricing disclosed. The company is family-controlled, led by Chairman Prashant Malladi, Managing Director Shreya Sistla, and Co-Founder & Vice Chairman V. N. Gopalakrishnan, with board representation from private equity and strategic advisors. Sustainability credentials include EcoVadis Silver Medal (2024), CDP A rating for Climate Change (2025), and SBTi-validated targets of 58.8% GHG reduction by 2034 and net-zero by 2050.

Name

MALLADI LIMITED

Legal name

Malladi Drugs & Pharmaceuticals Ltd.

Website

https://malladi.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Malladi Drugs & Pharmaceuticals is a privately held Indian API manufacturer founded in 1980, producing Ephedrine, Pseudoephedrine, Phenylephrine, and specialty APIs across three facilities. It serves pharmaceutical companies in 60+ countries with 22 US FDA DMFs and 6 CEPs.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (API) Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

akta.pro secondary industries

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Chiral building blocks
• Custom synthesis services
• Contract manufacturing

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Production and supply of high-quality APIs including Phenylephrine HCL, Phenylephrine bi-tartrate, Pseudoephedrine, Ephedrine salts, and other APIs. Manufacturing serves pharmaceutical companies worldwide with extensive capacity and rigorous quality control.
2. Pharmaceutical Intermediates: Production of intermediates essential for synthesis of complex pharmaceuticals with advanced manufacturing techniques and stringent quality measures.
3. Chiral Building Blocks & Specialty Chemicals: Production of chiral building blocks for creating enantiomerically pure drugs with state-of-the-art facilities ensuring highest purity and quality.
4. Contract Manufacturing & Custom Synthesis: Custom chemistry for drug discovery, full compliance in development, and CMC dossier preparation for pharmaceutical companies.
5. Macrocyclic Compounds: Specialized manufacturing of macrocyclic compounds and other speciality chemicals across various therapeutic categories.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Malladi manufactures and supplies Active Pharmaceutical Ingredients (APIs) including Ephedrine salts, Pseudoephedrine, Phenylephrine HCL, and Phenylephrine bi-tartrate, along with pharmaceutical intermediates, chiral building blocks, and specialty chemicals. The company also provides contract manufacturing and custom synthesis services for drug discovery, including CMC dossier preparation. Products serve pharmaceutical companies globally across therapeutic categories such as anxiolytic, antihistamine, antitussive, and antiparkinsonian.

Product overview

Malladi is a pharmaceutical manufacturing company offering a diversified portfolio of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, chiral building blocks, and specialty chemicals across various therapeutic categories. The company's core products include key APIs such as Phenylephrine HCL, Phenylephrine bi-tartrate, Pseudoephedrine, and Ephedrine salts. Supporting the manufacturing operations are three production facilities (M1, M3, M5) in Tamil Nadu and Andhra Pradesh, an R&D center near Chennai, and comprehensive analytical chemistry services including characterization & impurity profiling, method development & validation, and quality assurance. The company operates with manufacturing certifications from USFDA, WHO, EDQM, ANSM, and TGA.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) High-quality Active Pharmaceutical Ingredients including Phenylephrine HCL, Phenylephrine bi-tartrate, Pseudoephedrine, Ephedrine salts, and specialty APIs such as Alprazolam, Bilastine, Bromazepam, Cannabidiol (synthetic), and others across anxiolytic, antihistamine, antianxiety, antitussive, and antiparkinsonian therapeutic categories. Manufactured under stringent quality control for pharmaceutical companies worldwide.
• Pharmaceutical Intermediates Advanced manufacturing intermediates essential for the synthesis of complex pharmaceuticals, produced using sophisticated manufacturing techniques and stringent quality measures for drug development and production.
• Chiral Building Blocks & Specialty Chemicals Chiral building blocks crucial for creating enantiomerically pure drugs, produced using state-of-the-art facilities and innovative processes ensuring the highest purity and quality for pharmaceutical advancements.
• Contract Manufacturing & Custom Synthesis Custom chemistry services for drug discovery, full compliance in development, and CMC dossier preparation for pharmaceutical companies. Includes specialized manufacturing of macrocyclic compounds and other specialty chemicals across various therapeutic categories.
• Characterization & Impurity Profiling Advanced structural, physicochemical, and impurity profiling services using NMR, FTIR, LC-MS/MS, GC-MS, UV-Vis Spectrophotometer, and CHN Elemental Analysis to ensure product quality and regulatory compliance.
• Method Development & Validation Regulatory-aligned method development and validation services including QbD-driven development for raw materials, in-process controls, intermediates, and APIs, along with pharmacopeial method verification (USP, BP/EP, IP, JP, CP).
• Analytical Control & Quality Assurance Comprehensive analytical systems and documentation frameworks supporting product quality, lifecycle management, and global regulatory submissions, including method transfer, in-process controls, release testing, and standards management.

Quantifiable outcome

• 22 DMFs filed with US FDA and other agencies
• +5 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Our Shoulder FoundationminorStrategic or Co-development Partner · 1 March 2025Partnership with Our Shoulder Foundation to renovate existing public toilet facility in Vanapadi Village, Ranipet, installing new hygienic equipment to serve local population with dignity and safety.
• Sri Aurobindo SocietycoreStrategic or Co-development Partner · 27 February 2024Partnership with Sri Aurobindo Society (SAS) to launch Centre of Excellence (CoE) at Bhavitha Centre, ZP Boys High School, Renigunta, Andhra Pradesh. Part of SAS's broader 'Rupantar' program for inclusive education. Malladi contributed ₹39.66 lakhs (₹7.06 lakhs utilized as of June 2024) for infrastructure, teaching materials, content development in Telugu, and staff recruitment.
• Local Panchayat (Puliyankannu)minorOthers · 1 January 2024At request from local panchayat, Malladi funded and installed lighting infrastructure across Puliyankannu village, enhancing security and improving nighttime mobility.
• Swami Vivekananda Rural Development SocietycoreStrategic or Co-development Partner · 1 June 2023Partnered with Swami Vivekananda Rural Development Society for Gangaiamman Temple Pond Rejuvenation project in N M Kandigai Village, Ranipet. Also collaborated for construction of 10 toilet-and-bathroom units in Vidayiur Village, Tiruvallur and Kattupakkam Village, Ranipet.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Divi's Laboratories: Leading Indian API manufacturer and contract manufacturer specializing in complex generics, chiral APIs, and custom synthesis—directly comparable in product portfolio, regulatory scale, and export-led business model.
• Granules India: Indian API and finished dosage manufacturer with significant DMF filings and export presence—comparable as an Indian specialty API exporter with similar regulatory-driven moat.
• Piramal Pharma Solutions: Global CDMO offering API manufacturing and custom synthesis across complex chemistry—directly comparable to Malladi's custom synthesis and contract manufacturing business for innovator customers.
• Dishman Carbogen Amcis: Indian-headquartered CDMO with API, intermediates, and chiral chemistry services serving global pharma—directly comparable in contract manufacturing and complex organic synthesis capabilities.
• Laurus Labs: Indian API and CDMO player with fermentation and synthesis capabilities serving global generic and innovator pharma—comparable in scale, technology breadth, and export orientation.
• MSN Laboratories: Indian specialty API and intermediates manufacturer with strong DMF portfolio and global regulatory filings—directly comparable as a mid-sized Indian specialty API exporter serving global pharma.

Emerging players

• Syngene International: Indian CRO/CDMO with growing API and custom synthesis capabilities for global pharma—comparable as an Indian-headquartered contract manufacturer scaling into API services.

Broad incumbents

• Lonza Group: Global CDMO leader with extensive API and custom synthesis offerings—comparable as a broad incumbent operating in the same custom synthesis and complex API space, but at much larger scale.
• Aurobindo Pharma: Large Indian vertically-integrated pharmaceutical company with substantial API manufacturing operations including fermentation—comparable as a broad Indian incumbent with overlapping API/intermediates portfolio and global exports.
• Cambrex (Eurofins CDMO): Global small-molecule API and CDMO provider—comparable as a broad incumbent serving innovator pharma customers with custom synthesis and complex API services.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/Malladi_Drugs
• LinkedInlinkedin.com/company/malladi-drugs-and-pharmaceuticals-limited

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MALLADI LIMITED